Key Points
- CEO Bernd Brust bought 157,201 shares on Nov. 11 at $3.24 ($509,331.24) and 93,358 shares on Nov. 12 at $3.21 (~$299,679), totaling about $809,010, with the purchases disclosed in an SEC filing.
- Maravai recently missed quarterly expectations—a loss per share of $0.08 vs. an expected $0.06 and revenue of $41.63M vs. $49.02M—reports a negative net margin (-62.88%) and negative ROE, and has a ~ $830M market cap with an average analyst rating of "Hold" (avg target $5.22).
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) CEO Bernd Brust bought 93,358 shares of the company's stock in a transaction that occurred on Wednesday, November 12th. The stock was acquired at an average cost of $3.21 per share, for a total transaction of $299,679.18. Following the acquisition, the chief executive officer directly owned 250,559 shares of the company's stock, valued at $804,294.39. The trade was a 59.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Bernd Brust also recently made the following trade(s):
- On Tuesday, November 11th, Bernd Brust purchased 157,201 shares of Maravai LifeSciences stock. The shares were acquired at an average cost of $3.24 per share, with a total value of $509,331.24.
Maravai LifeSciences Stock Up 6.6%
Shares of MRVI traded up $0.22 during mid-day trading on Friday, reaching $3.47. The company's stock had a trading volume of 562,369 shares, compared to its average volume of 2,132,394. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.49. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.66 and a 12-month high of $6.21. The stock has a market cap of $884.82 million, a PE ratio of -4.13 and a beta of 0.34. The company's 50 day moving average is $3.03 and its 200 day moving average is $2.58.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The company had revenue of $41.63 million for the quarter, compared to analysts' expectations of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. Equities analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.
Analyst Ratings Changes
Several brokerages have issued reports on MRVI. Royal Bank Of Canada dropped their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Maravai LifeSciences has an average rating of "Hold" and an average target price of $5.22.
Check Out Our Latest Research Report on MRVI
Hedge Funds Weigh In On Maravai LifeSciences
Several institutional investors have recently added to or reduced their stakes in the stock. 12 West Capital Management LP lifted its holdings in shares of Maravai LifeSciences by 8.0% during the first quarter. 12 West Capital Management LP now owns 12,521,335 shares of the company's stock worth $27,672,000 after purchasing an additional 930,000 shares during the period. Mirabella Financial Services LLP raised its position in Maravai LifeSciences by 0.3% during the 2nd quarter. Mirabella Financial Services LLP now owns 3,750,000 shares of the company's stock worth $9,038,000 after buying an additional 10,049 shares during the last quarter. Monaco Asset Management SAM raised its position in Maravai LifeSciences by 315.0% during the 3rd quarter. Monaco Asset Management SAM now owns 3,656,337 shares of the company's stock worth $10,494,000 after buying an additional 2,775,372 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Maravai LifeSciences by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,984,045 shares of the company's stock worth $7,193,000 after acquiring an additional 319,679 shares during the period. Finally, Philosophy Capital Management LLC purchased a new stake in shares of Maravai LifeSciences in the first quarter valued at about $5,731,000. Institutional investors and hedge funds own 50.25% of the company's stock.
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
